[PDF] Top 20 Una nación más allá de las fronteras

... The included clinical studies were discussed by their dif- ferences of eligible criteria, chemotherapy strategy, and implementation of radiotherapy, as well as the risk of bias of study evaluation using the new version ... See full document

... HER2-overexpressing breast cancer represents approximately 20% of human breast cancers and is associated with an increased risk of tumor recurrence and reduced overall survival [1, ...The ... See full document

... for patients with small tumors (< 2 cm) show a slightly greater OS advantage was provided by H/anthra- cycline-containing chemotherapy compared with H/ non-anthracycline-containing ...dence from the ... See full document

... originator trastuzumab is used worldwide, there are a number of other HER2-targeted therapies that have since been developed and used successfully, including lapatinib, pertuzumab, and trastuzumab ... See full document

... Tumor microenvironment is another key domain helping in maintenance of CSCs. Various elements like cytokine flux, tumor-associated immune cells, stromal cells, and CAFs impact chemokine receptor signaling, cytoskeletal ... See full document

... 0.31–0.89, P = 0.005). EFS, ORR and clinical benefit rate (CBR) were also significantly better with combined therapy in the HER2 + ...the HER2 negative ...(8 patients, 2.7%) compared to ... See full document

... untreated patients with MBC and associated with an increased risk of disease progression and worse long- term ...to trastuzumab treat- ment remains ... See full document

... of breast cancer, together with the identification of the driving genetic alterations and signaling pathways, has led to the clinical development of a number of suc- cessful molecular targeted ...of ... See full document

... cost-minimisation analysis, other potential impacts were not relevant to the question and had not been included in the ...impactful. From the perspective of the hospital, SC administration would open ... See full document

... to trastuzumab. A) Loss of PTEN protein can impair efficacy of trastuzumab; B) mutation of PI3KCA gene sequence C) Overexpression of DARPP-32 and its truncated form t-DARPP, leading to increased ... See full document

... whether neoadjuvant chemotherapy can improve survival in LABC patients remains ...that neoadjuvant therapy does not worsen survival but it does improve ...of patients have significant primary ... See full document

... the analysis of the primary end point, the ad- dition of pertuzumab was found to be associated with a significantly higher rate of invasive-disease– free survival than placebo ...1.00; P = ...139 ... See full document

... all patients, paclitaxel 80 mg/m² was given weekly start- ing on day 1 for 16 weeks; cisplatin 25 mg/m² was given weekly on day 1, 8, and 15 every 28 days for 4 ...For HER2-positive patients in ... See full document

... Immunohistochemistry was performed with 4 µ m formalin- fixed, paraffin-embedded sections. After deparaffinization and rehydration, 3% H 2 O 2 solution was used to block endogenous peroxidase at room temperature. Antigen ... See full document

... of patients. However, the values of HER2 GCN remain stable when the patients continue to achieve treatment bene fi t (Figure 4), implying that samples obtained in a period of the same disease status ... See full document

... metastatic breast cancer (MBC), introduction of the anti- HER2 (human epidermal growth factor receptor-2) directed therapies including trastuzumab, pertuzumab, lapatinib, and/or ... See full document

... for patients short of breast skin, a more logical comparison assessing the impact of NAC on SSM‑IBR would evaluate direct‑to‑implant, one‑stage implant ...sufficient patients in the study cohort to ... See full document

... or neoadjuvant therapy. Patients were excluded if they had the following conditions: (1) contra- indications to chemotherapy; (2) impaired car- diac function ...All patients provided written informed ... See full document

... with NeoAdjuvant Herceptin)), was a parallel-group, open-label RCT (n = 595) directly comparing IV with SC administration of trastuzumab during 1 year of treat- ment and 2 years of treatment-free follow-up ... See full document

... of trastuzumab ther- apy beyond progression could improve PFS and OS in HER2+MBC ...and trastuzumab-containing regimes did not increase the risk for CNS metastasis after initiation of ... See full document